Skip to main content

Table 2 Univariate Cox proportional hazard regression analysis for overall survival and relapse-free survival in overall osteosarcoma patients

From: The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

Characteristics

No.

OS

P

RFS

P

HR (95% CI)

HR (95% CI)

Age, yr., ≥ 30 (vs. <  30)

11/35

2.632 (0.972–7.127)

0.057

3.252 (1.283–8.242)

0.013

Sex, male (vs. female)

25/35

1.875 (0.530–6.635)

0.329

2.363 (0.674–8.282)

0.179

Tumor size, cm, >  8 (vs. ≤ 8)

17/35

4.371 (1.393–13.717)

0.011

3.159 (1.166–8.557)

0.024

Stage, I

11/35

1

0.008

1

0.014

 II

19/35

8.528 (1.098–66.238)

0.040

10.139 (1.323–77.728)

0.026

 III-IV

5/35

28.907 (3.133–266.703)

0.003

26.685 (2.862–248.802)

0.004

Distant metastasis, presence (vs. absence)

5/35

5.404 (1.661–17.578)

0.005

4.174 (1.298–13.418)

0.016

Histological grade, high (vs. low)

24/35

10.347 (1.362–78.639)

0.024

11.623 (1.541–87.689)

0.017

PARP1, positive (vs. negative)

26/35

7.834 (1.030–59.563)

0.047

8.355 (1.109–62.967)

0.039

γH2AX, positive (vs. negative)

20/35

9.192 (2.052–41.166)

0.004

6.540 (1.858–23.023)

0.003

BRCA1, positive (vs. negative)

17/35

2.796 (0.967–8.088)

0.058

3.741 (1.318–10.620)

0.013

BRCA2, positive (vs. negative)

16/35

5.194 (1.652–16.331)

0.005

3.436 (1.253–9.424)

0.017

CSddrm, score 3–4 (vs. score 0–2)

18/35

3.681 (1.712–7.913)

< 0.001

13.249 (2.900–60.537)

< 0.001

  1. OS overall survival, RFS relapse-free survival, HR hazard ratio, 95% CI 95% confidence interval, CSddrm the combined score for the immunohistochemical expression of PARP1, γH2AX, BRCA1, and BRCA2